Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis

Abstract Background The purpose of this study was to compare the treatment efficacy and safety of re-irradiation (re-RT) using stereotactic ablative radiotherapy (SABR) and initial SABR for primary, recurrent lung cancer or metastatic lung tumor. Methods A retrospective review of the medical records...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tae Hoon Lee, Dong-Yun Kim, Hong-Gyun Wu, Joo Ho Lee, Hak Jae Kim
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Lung cancer Metastasis Stereotactic radiation therapy Re-irradiation Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ca005cff378c4d6d829ee2f78befc8c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca005cff378c4d6d829ee2f78befc8c8
record_format	dspace
spelling	oai:doaj.org-article:ca005cff378c4d6d829ee2f78befc8c82021-11-21T12:14:16ZTreatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis10.1186/s13014-021-01948-61748-717Xhttps://doaj.org/article/ca005cff378c4d6d829ee2f78befc8c82021-11-01T00:00:00Zhttps://doi.org/10.1186/s13014-021-01948-6https://doaj.org/toc/1748-717XAbstract Background The purpose of this study was to compare the treatment efficacy and safety of re-irradiation (re-RT) using stereotactic ablative radiotherapy (SABR) and initial SABR for primary, recurrent lung cancer or metastatic lung tumor. Methods A retrospective review of the medical records of 336 patients who underwent lung SABR was performed. Re-RT was defined as the overlap of the 70% isodose line of second-course SABR with that of the initial radiotherapy, and 20 patients were classified as the re-RT group. The median dose of re-RT using SABR was 54 Gy (range 48–60 Gy), and the median fraction number was 4 (range 4–6). One-to-three case-matched analysis with propensity score matching was used, and 60 patients were included in the initial SABR group of the matched cohort. Results The 1- and 2-year local control rates for the re-RT group were 73.9% and 63.3% and those for the initial SABR group in the matched cohort were 92.9% and 87.7%, respectively (P = 0.013). There was no difference in distant metastasis-free, progression-free, and overall survival rates. The crude grade ≥ 2 toxicity rates were 40.0% for the re-RT group and 25.0% for the initial SABR group (P = 0.318). Re-RT group had higher acute grade ≥ 2 toxicity rates (25.0% vs 5.0%, P = 0.031). One incident of grade 3 toxicity (pulmonary) was reported in the re-RT group; there was no grade 4‒5 toxicity. Conclusions The local control rate of the in-field re-RT SABR was lower than that of the initial SABR without compromising the survival rates. The toxicity of re-RT using SABR was acceptable.Tae Hoon LeeDong-Yun KimHong-Gyun WuJoo Ho LeeHak Jae KimBMCarticleLung cancerMetastasisStereotactic radiation therapyRe-irradiationMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENRadiation Oncology, Vol 16, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lung cancer Metastasis Stereotactic radiation therapy Re-irradiation Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Lung cancer Metastasis Stereotactic radiation therapy Re-irradiation Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tae Hoon Lee Dong-Yun Kim Hong-Gyun Wu Joo Ho Lee Hak Jae Kim Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
description	Abstract Background The purpose of this study was to compare the treatment efficacy and safety of re-irradiation (re-RT) using stereotactic ablative radiotherapy (SABR) and initial SABR for primary, recurrent lung cancer or metastatic lung tumor. Methods A retrospective review of the medical records of 336 patients who underwent lung SABR was performed. Re-RT was defined as the overlap of the 70% isodose line of second-course SABR with that of the initial radiotherapy, and 20 patients were classified as the re-RT group. The median dose of re-RT using SABR was 54 Gy (range 48–60 Gy), and the median fraction number was 4 (range 4–6). One-to-three case-matched analysis with propensity score matching was used, and 60 patients were included in the initial SABR group of the matched cohort. Results The 1- and 2-year local control rates for the re-RT group were 73.9% and 63.3% and those for the initial SABR group in the matched cohort were 92.9% and 87.7%, respectively (P = 0.013). There was no difference in distant metastasis-free, progression-free, and overall survival rates. The crude grade ≥ 2 toxicity rates were 40.0% for the re-RT group and 25.0% for the initial SABR group (P = 0.318). Re-RT group had higher acute grade ≥ 2 toxicity rates (25.0% vs 5.0%, P = 0.031). One incident of grade 3 toxicity (pulmonary) was reported in the re-RT group; there was no grade 4‒5 toxicity. Conclusions The local control rate of the in-field re-RT SABR was lower than that of the initial SABR without compromising the survival rates. The toxicity of re-RT using SABR was acceptable.
format	article
author	Tae Hoon Lee Dong-Yun Kim Hong-Gyun Wu Joo Ho Lee Hak Jae Kim
author_facet	Tae Hoon Lee Dong-Yun Kim Hong-Gyun Wu Joo Ho Lee Hak Jae Kim
author_sort	Tae Hoon Lee
title	Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
title_short	Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
title_full	Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
title_fullStr	Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
title_full_unstemmed	Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
title_sort	treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/ca005cff378c4d6d829ee2f78befc8c8
work_keys_str_mv	AT taehoonlee treatmentoutcomesofreirradiationusingstereotacticablativeradiotherapytolungapropensityscorematchinganalysis AT dongyunkim treatmentoutcomesofreirradiationusingstereotacticablativeradiotherapytolungapropensityscorematchinganalysis AT honggyunwu treatmentoutcomesofreirradiationusingstereotacticablativeradiotherapytolungapropensityscorematchinganalysis AT jooholee treatmentoutcomesofreirradiationusingstereotacticablativeradiotherapytolungapropensityscorematchinganalysis AT hakjaekim treatmentoutcomesofreirradiationusingstereotacticablativeradiotherapytolungapropensityscorematchinganalysis
_version_	1718419150169178112

Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis

Ejemplares similares